Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics Names New Distribution Partners

NEW YORK (GenomeWeb) – Rubicon Genomics today said that it has signed distribution deals with new partners covering parts of Europe, North Africa, and Asia, further expanding the market reach for its DNA library preparation kits for arrays and Illumina next-generation sequencing platforms.

The new distributors are CliniSciences in France, Spain, and North Africa; Nerliens Meszansky covering Norway; Shanghai Nanodigmnio Biotechnology in China; and GeneLabs Life Science serving customers in Taiwan. Products covered under the deals include Rubicon's ThruPLEX DNA-seq, PicoPLEX DNA-seq, and PicoPLEX WGA Kits.

"Our strategy of expanding our global network of distributors is working well — product sales of our DNA library prep kits are up more than 50 percent in the first nine months of 2014 compared to the same period in 2013," Rubicon Genomics CEO James Koziarz said in a statement.

Terms of the distribution deals were not disclosed.

The Ann Arbor, Mich.-based firm also said that it has appointed Karl Hecker as its new VP of product development. Hecker previously held product development positions at Invitrogen, PerkinElmer, Transgenomic, Quidel, and HTG Molecular Diagnostics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.